Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03602547
Recruitment Status : Recruiting
First Posted : July 27, 2018
Last Update Posted : July 3, 2019
Sponsor:
Information provided by (Responsible Party):
AnewPharma

Brief Summary:
This study was a one-arm, single-center, phase II clinical study. Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days a treatment cycle until the disease progresses , the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.

Condition or disease Intervention/treatment Phase
Mucosal Melanoma Drug: CM082 plus JS001 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Study of CM082 Combined With JS001 in the Treatment of Advanced Mucosal Melanoma.
Actual Study Start Date : July 31, 2018
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: CM082 plus JS001
Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
Drug: CM082 plus JS001
CM082:200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.




Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: 12 months ]
    The proportion of patients with complete remission (CR) and partial remission (PR) in all patients.Disease progression will be evaluated according to Response Evaluation Criteria in Solid Tumors V 1.1.


Secondary Outcome Measures :
  1. Disease Control Rate [ Time Frame: 12 months ]
    The proportion of patients with complete remission (CR),partial remission (PR) and stable diseasein(SD) all patients.Disease progression will be evaluated according to Response Evaluation Criteria in Solid Tumors V 1.1 and Immune-related Response Criteria.

  2. Duration of Response [ Time Frame: 12 months ]
    The time interval between the first time of being evaluated as complete response (CR) or partial response (PR) and the first time of being evaluated as progressed disease(PD).Disease progression will be evaluated according to Response Evaluation Criteria in Solid Tumors V 1.1 and Immune-related Response Criteria.

  3. Time to Response [ Time Frame: 12 months ]
    Time from randomization to complete response (CR) or partial response (PR).Disease progression will be evaluated according to Response Evaluation Criteria in Solid Tumors V 1.1 and Immune-related Response Criteria.

  4. Progression-free survival [ Time Frame: 12 months ]
    The internal between the date of randomization and the date of disease progression, unaccepted toxicity, or death

  5. Overall survival [ Time Frame: 36 months ]
    The internal between the date of randomization and the date of death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of recurrence after surgery, inoperable resection or metastasis advanced mucinous melanoma (III/IV period).
  • Has not received any systemic anti-tumor medication (previously adjuvant or neoadjuvant therapy is required, but the treatment should be completed for at least 4 weeks prior to the first dose of study drug, and all related toxicity events have returned to normal or no more than Grade I of CTCAE 4.03, except for hair loss).
  • Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1.
  • Life expectancy of at least 12 weeks.
  • All patients should provid tumor tissue specimens (preferably fresh tissue specimens) for PD-L1 expression analysis prior to enrollment.
  • There is at least one measurable lesion according to the RECIST 1.1 standard and the lesion has not received radiotherapy.
  • Patients may have a history of brain/mesis metastases, but must undergo topical treatment(surgery/radiotherapy) and be clinically stable for at least 3 months prior to the start of the study .If orticosteroids have been used before, they should be discontinued for at least 2 weeks before the first dose of study drug.
  • The level of organ function must meet the following requirements (7 days before the first dose of study drug):

    • Bone marrow: Absolute neutrophil count (ANC) ≥ 1.5 × 109 / L, platelet (PLT) ≥ 100 × 109 / L, hemoglobin (HB) ≥ 9g / dL (no blood transfusion or receiving blood components within 14 days before detection);
    • Liver: serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal(ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5*ULN (if liver metastasis, AST, ALT allowed) ≤ 5 *ULN);
    • Serum creatinine ≤ 1.5*ULN and endogenous creatinine clearance ≥ 50mL / min (Cockcroft-Gault formula);
    • Well-controlled hypertensive patients can be enrolled;
    • International normalized ratio (INR), activated partial thromboplastin time (aPTT) ≤ 1.5 *ULN for patients who have not received anticoagulant therapy; patients who receive anticoagulant therapy should be treated within the requirements of label
    • Urine protein ≤ 1+, if urine protein > 1+, 24 hours urine protein measurement is required, the total amount of which needs ≤ 1 gram;
    • FT3, FT4, TSH normal or abnormal has no clinical significance;
    • The heart function is normal, that is, the electrocardiogram is normal or abnormal has no clinical significance. The echocardiography shows that the left ventricular ejection fraction (LVEF) is greater than 50%.
  • Serum pregnancy test results must be negative within 7 days prior to the first dose of the test drug for women of childbearing age; males with fertility or women who are at risk of pregnancy must use highly effective methods of contraception throughout the trial (eg oral contraceptives, pIntrauterine device, controlled libido or barrier contraceptive method combined with spermicide), and continued contraception for 12 months after the end of treatment.
  • Ability to understand the nature of this trial and give written informed consent.Willingness and ability to comply with trial and follow-up procedures

Exclusion Criteria:

  • Patients who have previously received anti-PD-1, anti-PD-L1, anti-PD-L2 therapy, or VEGFR TKI therapy.
  • Patients currently receiving anti-tumor treatment
  • Patients who participated in or were participating in other drug/therapy clinical trials within 4 weeks prior to the first dose of the study drug.
  • Patients who received large surgery within 4 weeks before the first dose of the test drug or has not recovered from the side effects of this operation, received live vaccination or immunotherapy within 4 weeks before the first dose of the test drug, and radiotherapy was performed within 2 weeks.

In the past 5 years, there have been history of malignant tumors other than mucosal melanoma, except for cured skin basal cell carcinoma, cutaneous squamous cell carcinoma, early prostate cancer, and cervical carcinoma in situ.

  • Hematopoietic stimulating factors were received within 1 week prior to the first dose of the study drug, such as granulocyte colony-stimulating factor (G-CSF) and erythropoietin.
  • HIV antibody or Treponema pallidum antibody test results are positive.
  • If HBsAg or HBcAb is positive, HBV DNA should be tested.Patients should be excluded if the measurement is above the upper limit of the normal range.If HCV antibody is positive, HCV DNA should be tested.Patients should be excluded if the measurement is above the upper limit of the normal range.
  • Those known to be allergic to recombinant humanized PD-1 monoclonal antibody drugs and their components; those known to be allergic to CM-082 and any of its excipients.
  • A large amount of pleural or ascites with clinical symptoms and requiring symptomatic treatment.
  • Active lung disease (eg, interstitial pneumonia, pneumonia, obstructive pulmonary disease, asthma) or a history of active tuberculosis.
  • Have any clinical problems out of control, including but not limited to:

    • Persistent or active (severe) infection;
    • Hypertension that is not effectively controlled (blood pressure lasts greater than 150/90mmHg);
    • Diabetes that is not effectively controlled;
    • Heart disease, defined as grade III/IV congestive heart failure or heart block defined by the New York Heart Association
    • Having a history of or suspected of having an autoimmune disease;Having a history of any kind of disease requiring treatment with a steroid/immunosuppressive, such as: pituitary inflammation, colitis, hepatitis, nephritis, hyperthyroidism, Hypothyroidism, etc.;
    • The following situation occurred within 6 months before the first dose:

      • Deep vein thrombosis or pulmonary embolism;
      • myocardial infarction;
      • severe or unstable arrhythmia or angina;
      • percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass grafting;
      • Cerebrovascular accident, transient ischemic attack, and cerebral embolism.
  • The patient has any condition that affects the swallowing of the drug, as well as any conditions that affect the course of treatment (absorption, distribution, metabolism, or excretion) of the test drug, including any type of gastrointestinal resection or surgical history.
  • Have received a stem cell transplant or an organ transplant.
  • Has a history of psychotropic substance abuse which is unable to quit or has a history of mental disorders.
  • Patients who need to use during the study or have used or the following drugs within 14 days prior to the first dose: CYP3A4 strong inhibitor or strong inducer; warfarin or any other coumarin derivative anticoagulant.
  • The investigator judges other severe, acute or chronic medical illness or laboratory abnormalities that may increase the risk associated with the study or may interfere with the interpretation of the findings.
  • The investigator judged that the patient's compliance was poor or that there were other conditions that were not suitable for the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03602547


Contacts
Layout table for location contacts
Contact: Jun Guo, M.D 010-88196951 guoj307@126.com

Locations
Layout table for location information
China, Beijing
Beijing Cancer Hospital Recruiting
Beijing, Beijing, China, 100142
Contact: Jun Guo, M.D    010-88196951    guoj307@126.com   
Sponsors and Collaborators
AnewPharma
Investigators
Layout table for investigator information
Study Chair: Jun Guo, M.D Beijing Cancer Hospital

Layout table for additonal information
Responsible Party: AnewPharma
ClinicalTrials.gov Identifier: NCT03602547     History of Changes
Other Study ID Numbers: CM082-CA-II-202
First Posted: July 27, 2018    Key Record Dates
Last Update Posted: July 3, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas